Filing Flows › Evofem Biosciences (EVFM) › Q4 2025
Evofem Biosciences (EVFM) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 11, 2026
Evofem Biosciences (EVFM) reported revenue of $9.6M for the fourth quarter 2025 (Q4 2025), +35% from a year earlier and +93% from the quarter before. Operating margin was 35.0%, net earnings $2.8M (29.2% of revenue).
Evofem Biosciences, Q4 2025: revenue $9.6M (+35% year over year), operating margin 35.0%, net earnings $2.8M, operating cash flow $31K. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.6M | +93% | +35% |
| Operating profit | $3.3M | +252% | — |
| Net earnings | $2.8M | — | — |
| Operating cash flow | $31K | -91% | — |
| Free cash flow | $28K | -92% | — |
What changed
Revenue was $9.6M in Q4 2025, up 35% year over year and up 93% from the previous quarter.
Operating profit was $3.3M, a 35.0% margin (up 49.1 points year over year). Total costs fell 23% while revenue rose 35%. The fastest-growing cost line was Cost of revenue (+71%). Net earnings were $2.8M. The effective tax rate was 0.0%.
Operating cash flow was $31K, 1% of net earnings. Non-cash charges added back $94K of depreciation and amortization and $42K of share-based compensation. Working capital and other items used $2.9M. Capital expenditures of $3K left free cash flow of $28K.
Questions
What was Evofem Biosciences' revenue in the fourth quarter 2025?
Evofem Biosciences (EVFM) reported revenue of $9.6M for the fourth quarter 2025 (Q4 2025), +35% from a year earlier and +93% from the quarter before.
Was Evofem Biosciences profitable in the fourth quarter 2025?
Operating profit was $3.3M (35.0% of revenue) and net earnings $2.8M.
Source: Evofem Biosciences 10-K on SEC EDGAR.